---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-199857"
form_type: "8-K"
ticker: "PMVP"
cik: "0001699382"
company_name: "PMV Pharmaceuticals, Inc."
filed_at: "2025-09-10T23:59:59+00:00"
generated_at: "2026-05-17T07:02:03.594622+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# PMV Pharma reports 33% ORR for rezatapopt in TP53 Y220C tumors; NDA for ovarian cancer planned Q1 2027

## Summary
- Overall ORR 33% (32/97 evaluable patients) across 8 tumor types; median duration of response 6.2 months.
- Ovarian cancer cohort: 43% ORR (19/44), median DOR 7.6 months, includes one confirmed complete response.
- Safety profile manageable: most TRAEs Grade 1-2, no discontinuations due to Grade 3 AST/ALT elevations, 3.7% discontinuation rate.
- FDA feedback supports NDA for platinum resistant/refractory ovarian cancer; plan to enroll 20-25 more patients by Q1 2026.
- NDA submission for rezatapopt in ovarian cancer targeted for end of Q1 2027.

## SEC filing metadata
- accession: 0001193125-25-199857
- form_type: 8-K
- ticker: PMVP
- cik: 0001699382
- company_name: PMV Pharmaceuticals, Inc.
- filed_at: 2025-09-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1699382/000119312525199857/0001193125-25-199857-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1699382/000119312525199857/d90438d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-199857
- JSON: https://secwatch.observer/filing/0001193125-25-199857.json
- Plain text: https://secwatch.observer/filing/0001193125-25-199857.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.